Objective: To evaluate the efficacy and safety of subcutaneous immunotherapy with a standardized Dermatophagoides pteronyssinus extract for allergic rhinitis.
Method: Sixty-eight patients with allergic rhinitis who received specific immunotherapy with a standardized dermatophagoides pteronyssinus extract were enrolled in this study. The clinical symptoms and signs were scored before and 2 years after treatment. Side effects were registered. Symptom and side effect scores were assessed to evaluate the clinical efficacy and safety.
Result: There was a significant difference (P < 0.01) in symptom and medication scores between the two groups tow years after treatment. The patients had fewer symptoms and lower intake of medication. No severe systemic reactions were registered.
Conclusion: Immunotherapy with a standardized dermatophagoides pteronyssinus extract is effective and safe to treat patients clinically sensitive to this allergen.